Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas
July 13, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
July 07, 2021 07:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results
May 12, 2021 16:05 ET
|
Cyclacel
- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors - - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition - - Following...
Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update
May 05, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
March 16, 2021 16:05 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
March 15, 2021 07:16 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock
March 12, 2021 08:30 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
March 11, 2021 16:01 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 16:05 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results
February 19, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...